Cantex Pharmaceuticals, Inc.
http://www.cantex.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cantex Pharmaceuticals, Inc.
Tech Transfer Roundup: How Can Translational Research Help With The Next Pandemic?
Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.
Deal Watch: Roche Terminates Gene Therapy Alliance, Partners In IBD With Synlogic
Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.
Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Start-Up Previews (6/05)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, New Drugs for Myocardial Infarction, features profiles of ArgiNOx Pharmaceuticals, ParinGenix and VasoGenix Pharmaceuticals. Plus these Start-Ups Across Health Care: AngioScore, Hamilton Pharmaceuticals, Ikaria, Light BioScience and Potentia Pharmaceuticals.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice